DA
ITCI

Duality Advisers’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Duality Advisers’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-32,805
Closed -$2.08M – 745
2023
Q2 		$2.08M Buy
+32,805
New +$2.04M 0.26% 148
2023
Q1 		– Sell
-23,809
Closed -$1.26M – 805
2022
Q4 		$1.26M Sell
23,809
-30,273
-56% -$1.52M 0.14% 258
2022
Q3 		$2.52M Buy
54,082
+2,257
+4% +$118K 0.27% 140
2022
Q2 		$2.96M Buy
+51,825
New +$2.94M 0.29% 112

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Duality Advisers's ITCI Position: Q3 2023 in Review

Duality Advisers sold out of Intra-Cellular Therapies Inc. (ITCI) in Q3 2023, closing a stake of 32,805 shares — an estimated $2.08M sold.

Duality Advisers first reported a position in ITCI in Q2 2022 and held it in 4 quarters. The position peaked at $2.96M in Q2 2022. 292 funds tracked by Wall St. Rank hold ITCI as of Q3 2023.

  • Duality Advisers reported no remaining Intra-Cellular Therapies Inc. position as of Q3 2023 after selling out during the quarter.
  • Duality Advisers sold 32,805 Intra-Cellular Therapies Inc. shares in Q3 2023, an estimated $2.08M.
  • Duality Advisers first reported a position in Intra-Cellular Therapies Inc. in Q2 2022 and held it in 4 quarters.
  • Duality Advisers's Intra-Cellular Therapies Inc. position peaked at $2.96M in Q2 2022.
  • 292 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2023.

Based on Duality Advisers's 13F filing for Q3 2023, filed 2 Nov 2023.